Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + R-EPCH in Richter's Transformation
NCT04679012Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2021
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of polatuzumab vedotin in Richter syndrome (RS), sponsored by Weill Cornell Medicine. Started Sep 2021; status: active, not recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
Richter syndrome (RS)
Beyond the preview
Go deeper on NCT04679012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679012.